Nanostructured lipid carriers containing a high percentage of a pluronic copolymer increase the biodistribution of novel PDE4 inhibitors for the treatment of traumatic hemorrhage

Journal of Biomedical Nanotechnology

Volumn 10, Issue 8, 2014, Pages 1520-1535

  Hsieh, Pei Wen ^a   Wen, Chih Jen ^b,c   Yu, Huang Pin ^b,c   Aljuffali, Ibrahim A ^d   Huang, Ya Huei ^a   Fang, Jia You ^a,e,f  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Biodistribution; Nanostructured lipid carriers (NLCs); PDE4 inhibitor; Pharmacokinetics; Traumatic hemorrhage

Indexed keywords

CARDIOVASCULAR SYSTEM; DRUG THERAPY; MEDICAL NANOTECHNOLOGY; PATHOLOGY;

ACUTE LUNG INFLAMMATIONS; BIODISTRIBUTIONS; HISTOLOGICAL EXAMINATION; NANOSTRUCTURED LIPID CARRIERS; PDE4 INHIBITOR; POLYETHYLENE GLYCOL (PEG); SUSTAINED DRUG RELEASE; TRAUMATIC HEMORRHAGE;

PHARMACOKINETICS;

AMINOTRANSFERASE; DRUG CARRIER; DRUG METABOLITE; DSM RX 78; EFB 1; LIPID; MACROGOL; NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; PHOSPHODIESTERASE IV INHIBITOR; POLOXAMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN; CIRCULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; EX VIVO STUDY; HEMORRHAGIC SHOCK; HISTOPATHOLOGY; HYDROLYSIS; IN VIVO STUDY; INFLAMMATION; INTESTINE INJURY; LIVER INJURY; LUNG INJURY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; ORGAN DISTRIBUTION; PHYSICAL CHEMISTRY; PNEUMONIA; RAT; SUSTAINED DRUG RELEASE;

ANALYSIS OF VARIANCE; ANIMALS; BENZAMIDES; DRUG CARRIERS; FLUORESCENT DYES; LIPIDS; MALE; NANOSTRUCTURES; PHOSPHODIESTERASE 4 INHIBITORS; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84899696304     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1858     Document Type: Article

References (50)

1. Y. Wang and L. Chen, Quantum dots, lighting up the research and development of nanomedicine. Nanomed.-Nanotechnol. Biol. Med. 7, 385 (2011).
2. I. Szelenyi, Nanomedicine: Evolutionary and revolutionary developments in the treatment of certain inflammatory diseases. Inflamm. Res. 61, 1 (2012).
3. M. J. Mirzayan, C. Probst, M. Samii, C. Krettek, A. Gharabaghi, H. C. Pape, M. van Griensven, and A. Samii, Histopathological features of the brain, liver, kidney and spleen following an innovative polytrauma model of the mouse. Exp. Toxicol. Pathol. 64, 133 (2012).
4. D. S. Kauvar, R. Lefering, and C. E. Wade, Impact of hemorrhage on trauma outcome: An overview of epidemiology, clinical presentations, and therapeutic considerations. J. Trauma 66, S3 (2006).
5. T. V. Colby, J. Fukuoka, S. P. Ewaskow, R. Helmers, and K. O. Leslie, Pathologic approach to pulmonary hemorrhage. Ann. Diagn. Pathol. 5, 309 (2001).
6. D. E. Fry, Sepsis, systemic inflammatory response, and multiple organ dysfunction: The mystery continues. Am. Surg. 78, 1 (2012).
7. J. Deree, J. Martins, T. de Campos, J. G. Putnam, W. H. Loomis, P. Wolf, and R. Coimbra, Pentoxifylline attenuates lung injury and modulates transcription factor activity in hemorrhagic shock. J. Surg. Res. 143, 99 (2007).
8. T. W. Costantini, W. H. Loomis, J. G. Putnam, D. Drusinsky, J. Deree, S. Choi, P. Wolf, A. Baird, B. Eliceiri, V. Bansal, and R. Coimbra, Burn-induced gut barrier injury is attenuated by phosphodiesterase inhibition: Effects on tight junction structural proteins. Shock 31, 416 (2009).
9. V. Boswell-Smith and D. Spina, PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. Int. J. COPD 2, 121 (2007).
10. D. Spina, PDE4 inhibitors: Current status. Br. J. Pharmacol. 155, 308 (2008).
11. P. M. Calverley, F. Sanchez-Toril, A. McIvor, P. Teichmann, D. Bredenbroeker, and L. M. Fabbri, Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 176, 154 (2007).
12. H. P. Yu, P. W. Hsieh, Y. J. Chang, P. J. Chung, L. M. Kuo, and T. L. Hwang, DSM-RX78, a new phosphodiesterase inhibitor, suppresses superoxide anion production in activated human neutrophils and attenuates hemorrhagic shock-induced lung injury in rats. Biochem. Pharmacol. 78, 983 (2009).
13. H. P. Yu, P. W. Hsieh, Y. J. Chang, P. J. Chung, L. M. Kuo, and T. L. Hwang, 2-(2-fluorobenzamido)benzoate ethyl ester (EFB-1) inhibits superoxide production by human neutrophils and attenuates hemorrhagic shock-induced organ dysfunction in rats. Free Radic. Biol. Med. 50, 1737 (2011).
14. Z. Su, J. Niu, Y. Xiao, Q. Ping, M. Sun, A. Huang, W. You, X. Sang, and D. Yuan, Effect of octreotide-polyethylene glycol (100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine. Mol. Pharm. 8, 1641 (2011).
15. Y. K. Lin, Z. R. Huang, R. Z. Zhuo, and J. Y. Fang, Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int. J. Nanomed. 5, 117 (2010).
16. A. R. Kochanek, E. Y. Fukudome, Y. Li, E. J. Smith, B. Liu, G. C. Velmahos, M. de Moya, D. King, and H. B. Alam, Histone deacetylase inhibitor treatment attenuates MAP kinase pathway activation and pulmonary inflammation following hemorrhagic shock in a rodent model. J. Surg. Res. 176, 185 (2012).
17. J. Y. Fang, Y. T. Liu, Y. B. Huang, T. L. Pan, H. H. Wang, and P. W. Hsieh, Pharmacokinetics, biodistribution, and toxicology following intravenous and oral administration of DSM-RX78 and EFB-1, two new 2-(2-fluorobenzamido) benzoate-based PDE4 inhibitors to rats. J. Pharm. Pharmacol. 65, 345 (2013).
18. A. V. Kabanov, E. V. Batrakova, and V. Y. Alakhov, Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release 82, 189 (2002).
19. Y. Wang, Y. Li, Q. Wang, J. Wu, and X. Fang, Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105/L101 mixed polymeric micelles. Yakugaku Zasshi 128, 941 (2008).
20. S. M. Ryan, G. Mantovani, X. Wang, D. M. Haddleton, and D. J. Brayden, Advances in PEGylation of important biotech molecules: Delivery aspects. Expert Opin. Drug Deliv. 5, 371 (2008).
21. K. S. Liu, C. J. Wen, T. C. Yen, K. C. Sung, M. C. Ku, J. J. Wang, and J. Y. Fang, Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers (NLCs) for efficient brain targeting. Nanotechnology 23, 095103 (2012).
22. S. H. Hsu, S. A. Al-Suwayeh, C. C. Chen, C. H. Chi, and J. Y. Fang, PEGylated liposomes incorporated with nonionic surfactants as an apomorphine delivery system targeting the brain: In vitro release and in vivo real-time imaging. Curr. Nanosci. 7, 191 (2011).
23. K. Sou, S. Inenaga, S. Takeoka, and E. Tsuchida, Loading of curcumin into macrophages using lipid-based nanoparticles. Int. J. Pharm. 352, 287 (2008).
24. M. J. Tsai, P. C. Wu, Y. B. Huang, J. S. Chang, C. L. Lin, Y. H. Tsai, and J. Y. Fang, Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int. J. Pharm. 423, 461 (2012).
25. L. Jia, J. Shen, D. Zhang, C. Duan, G. Liu, D. Zheng, X. Tian, Y. Liu, and Q. Zhang,In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int. J. Biol. Macromol. 50, 523 (2012).
26. H. Yuan, L. L. Wang, Y. Z. Du, J. You, F. Q. Hu, and S. Zeng, Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf. B: Biointerf. 60, 174 (2007).
27. R. H. Müller, S. A. Runge, V. Ravelli, A. F. Thünemann, W. Mehnert, and E. B. Souto, Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 68, 535 (2008).
28. S. D. Li and L. Huang, Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5, 496 (2008).
29. B. Romberg, W. E. Hennink, and G. Storm, Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25, 55 (2008).
30. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505 (2008).
31. R. Gill, X. Ruan, C. L. Menzel, S. Namkoong, P. Loughran, D. J. Hackam, and T. R. Billiar, Systemic inflammation and liver injury following hemorragic shock and peripheral tissue trauma involve functional TLR9 signaling on bone marrow-derived cells and parenchymal cells. Shock 35, 164 (2011).
32. M. Lauterbach, G. Horstick, T. Kempf, L. S. Weilemann, T. Münzel, and O. Kempski, Anti-inflammatory treatment with standardized human serum protein solution reduces local and systemic inflammatory response after hemorrhagic shock. Eur. Surg. Res. 38, 399 (2006).
33. I. P. Kaur, R. Bhandari, S. Bhandari, and V. Kakkar, Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 127, 97 (2008).
34. J. J. Wang, K. S. Liu, K. C. Sung, C. Y. Tsai, and J. Y. Fang, Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Eur. J. Pharm. Sci. 38, 138 (2009).
35. E. V. Batrakova, D. W. Miller, S. Li, V. Y. Alakhov, A. V. Kabanov, and W. F. Elmquist, Pluronic P85 enhances the delivery of digoxin to the brain: In vitro and in vivo studies. J. Pharmacol. Exp. Ther. 296, 551 (2001).
36. C. R. Maxwell, S. J. Kanes, T. Abel, and S. J. Siegel, Phosphodiesterase inhibitors: A novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129, 101 (2004).
37. R. W. Chen, A. J. Williams, Z. Liao, C. Yao, F. C. Tortella, and J. R. Dave, Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci. Lett. 418, 165 (2007).
38. E. de Montmollin and D. Annane, Year in review 2010: Critical care-multiple organ dysfunction and sepsis. Crit. Care 15, 236 (2011).
39. Y. P. de Visser, F. J. Walther, E. H. Laghmani, S. van Wijngaarden, K. Nieuwland, and G. T. M. Wagenaar, Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur. Respir. J. 31, 633 (2008).
40. X. Xu, C. Zhao, H. Yang, Y. Jian, Z. Zhang, and Y. Huang, Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers. Drug Deliv. 18, 485 (2011).
41. J. L. Perry, K. G. Reuter, M. P. Kai, K. P. Herlihy, S. W. Jones, J. C. Luft, M. Napier, J. E. Bear, and J. M. DeSimone, PEGylated PRINT nanoparticles: The impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett. 12, 5304 (2012).
42. H. J. Johnson, M. Semmler-Behnke, D. M. Brown, W. Kreyling, L. Tran, and V. Stone, Evaluting the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol. Appl. Pharmacol. 242, 66 (2010).
43. L. Jia, D. Zhang, Z. Li, C. Duan, Y. Wang, F. Feng, F. Wang, Y. Liu, and Q. Zhang, Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf. B: Biointerf. 80, 213 (2010).
44. X. Zhao, Y. Zhao, L. Geng, X. Li, X. Wang, Z. Liu, D. Wang, K. Bi, and X. Chen, Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: Evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier. J. Chromatogr. B 879, 3721 (2011).
45. T. N. Mayadas and X. Cullere, Neutrophil beta2 integrins: Moderators of life or death decisions. Trends Immunol. 26, 388 (2005).
46. M. van Griensven, M. Kuzu, M. Breddin, F. Bottcher, C. Kretteck, H. C. Pape, and T. Tschernig, Polymicrobial sepsis induces organ changes due to granulocyte adhesion in a murine two hit model of trauma. Exp. Toxicol. Pathol. 54, 203 (2002).
47. T. Ishihara, M. Takahashi, M. Higaki, Y. Mizushima, and T. Mizushima, Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents. Int. J. Pharm. 385, 170 (2010).
48. J. A. Clark and C. M. Coopersmith, Intestinal crosstalk: A new paradigm for understanding the gut as the "motor" of critical illness. Shock 28, 384 (2007).
49. P. W. Hsieh, T. L. Hwang, C. C. Wu, S. Z. Chiang, C. I. Wu, and Y. C. Wu, The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as antiinflammatory and anti-platelet aggregation agents. Bioorg. Med. Chem. Lett. 17, 1812 (2007).
50. H. P. Yu, Y. C. Hsieh, T. Suzuki, T. Shimizu, M. A. Choudhry, M. G. Schwacha, and I. H. Chaudry, Salutary effects of estrogen receptor-beta agonist on lung injury after trauma-hemorrhage. Am. J. Physiol. Lung Cell. Mol. Physiol. 290, L1004 (2006).